Thousands of patients’ lives, and those of their families, are impacted by rare endocrine diseases. We have an opportunity to improve things for these underserved people. Our seasoned team has extensive experience in drug discovery and development in endocrine GPCRs, and we’ve built a highly productive drug discovery organization.

Read below to learn more about the areas we’ve been working on. Then we’d love to hear what you need and what your patients struggle with so we can get to work on that, too.

Thousands of patients’ lives, and those of their families, are impacted by rare endocrine diseases. We have an opportunity to improve things for these underserved people. Our seasoned team has extensive experience in drug discovery and development in endocrine GPCRs, and we’ve built a highly productive drug discovery organization.

Read below to learn more about the areas we’ve been working on. Then we’d love to hear what you need and what your patients struggle with so we can get to work on that, too.

Conditions


Acromegaly is a rare, chronic, endocrine disorder caused, in most cases, by a growth hormone-producing pituitary tumor. Symptoms can vary, and may be due to the direct effect of GH and/or IGF-1 on various organs and systems, or can develop from the local effect of the tumor itself.

More than 25,000 people in the United States suffer from acromegaly, and the incidence is 116.9 new cases per million per year. An estimated 40% to 60% of patients are candidates for chronic pharmacological intervention.

Acromegaly patients must often endure the disruptive process of getting an injection every month. Our leading drug candidate, paltusotine, is a once-daily oral treatment that would make that annoyance a distant memory, and is the first agent in its class with reported clinical results.

Read more about paltusotine >

Neuroendocrine tumors originate from the neuroendocrine cells commonly found in the gut, lung, or pancreas. Symptoms vary according to tumor type and location in the body. They may include diarrhea, flushing, and shortness of breath (known as Carcinoid Syndrome). Symptoms may also result from tumor growth and invasiveness. NETs are the second most common GI cancer after colon cancer. In the United States, approximately 175,000 adults have NETs, and about 1,000 people are diagnosed each year. Paltusotine, our leading drug candidate, is also being developed for the treatment of NETs.

Read more about paltusotine >

Congenital HI is a rare disease marked by abnormally high levels of insulin that cause frequent episodes of hypoglycemia (low blood sugar). Babies can exhibit breathing difficulties, lethargy, irritability, or difficulty feeding. More serious complications such as seizures, vision loss, brain damage, and death can occur. Congenital HI occurs in approximately 1 in 30,000 to 50,000 new births in the United States, with a global prevalence of 1 in 50,000.

Read about the treatment we’re developing >

Cushing’s disease is caused by a benign ACTH-secreting pituitary adenoma, resulting in excessive cortisol secretion by the adrenal glands. Symptoms may include weight gain, fatty deposits, thinning skin that bruises easily, and fatigue. Globally, about 40 to 70 people per million are diagnosed with Cushing’s disease, with approximately 13,000 patients in the United States.

Read about the treatment we’re developing >

CAH is a group of genetic disorders affecting the adrenal glands and is caused by genetic mutations. Symptoms vary according to the type of CAH, but can be severe and include dehydration, cardiac arrhythmia, metabolic acidosis, and low blood sugar or sodium levels. In the U.S. and Europe, CAH occurs in 1 in 13,000-15,000 live births.

Read about the treatment we’re developing >

Crinetics was founded in endocrinology and we actively build long-term relationships with endocrinologists, giving us an in-depth understanding of the distinct challenges they face in treating patients with endocrine disease. We link our science to those challenges and come up with innovations that make the entire industry take notice. Like a once-daily pill to treat acromegaly. Ready to do some purposeful, inspiring science with us?